EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for locally advanced rectal cancer (North West Clinical Oncology Group-04 on behalf of the NCRI rectal cancer subgroup).

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

25 Oct 2017 Biomarkers information updated
04 Apr 2013 Planned end date changed from 1 Nov 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.
09 Feb 2013 New source identified and integrated (EudraCT2007-006701-25: European Clinical Trials Database).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com